United Therapeutics Corp (UTHR)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow UTHR in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on UTHR and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
UTHR at a glance
Key statistics
$23.76B
Market capitalization
- Previous close
- $553.88
- Open
- $551.05
- Day range
- $545.74 – $564.39
- Volume
- 163.9K
- Average volume (30 sessions)
- 911.4K
- Shares outstanding
- 42.89M
- Price / earnings
- 18.1
- Earnings per share
- $30.56
- Price / book
- 3.7
- Price / sales
- 7.5
- Beta (1 year, vs SPY)
- 0.25
Where the price sits in its year
52-week range
77% of the range
- Below the 52-week high
- -7.4%
- Above the 52-week low
- +37.9%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $528.46+4.8%
- 50-day average
- $515.23+7.5%
- 200-day average
- $527.57+5.0%
Between the conventional 30 and 70 bands.
+1.9%
1 week
+12.3%
1 month
+5.1%
3 months
+13.7%
Year to date
+27.8%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with UTHR
UTHR on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on UTHR.
See the plans →
Every planScreen names like UTHR
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on UTHR
Put UTHR on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on UTHR
See whether there is an open premium alert on UTHR, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
UTHR headlines
- Why Is United Therapeutics Stock Soaring Monday?
Benzinga · Mar 30, 2026
- United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening
Benzinga · Mar 2, 2026
- United Therapeutics Reports Early Success For External Liver Support In Acute Failure
Benzinga · Jan 26, 2026
- Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
GlobeNewswire Inc. · May 12, 2025
- District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia
GlobeNewswire Inc. · May 2, 2025
- United Therapeutics stock target lifted, keeps Buy on new treatment uses - Investing.com
Investing.com · Jul 8, 2024
SEC Form 4, most recent first
Insider filings
ROTHBLATT MARTINE A
−260
Chairperson & CEO, Director · Open-market sale
$141.13K · Oct 19, 2026
ROTHBLATT MARTINE A
−120
Chairperson & CEO, Director · Open-market sale
$65.96K · Oct 19, 2026
ROTHBLATT MARTINE A
−160
Chairperson & CEO, Director · Open-market sale
$86.17K · Oct 19, 2026
ROTHBLATT MARTINE A
−360
Chairperson & CEO, Director · Open-market sale
$193.09K · Oct 19, 2026
ROTHBLATT MARTINE A
+9.5K
Chairperson & CEO, Director · Option exercise
$1.12M · Oct 19, 2026
ROTHBLATT MARTINE A
−1.1K
Chairperson & CEO, Director · Open-market sale
$581.38K · Oct 19, 2026
ROTHBLATT MARTINE A
−416
Chairperson & CEO, Director · Open-market sale
$227.55K · Oct 19, 2026
ROTHBLATT MARTINE A
−120
Chairperson & CEO, Director · Open-market sale
$66.48K · Oct 19, 2026
About United Therapeutics Corp
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Silver Spring, MD
- Employees
- 1,400
- Listed since
- Jun 17, 1999
- Website
- unither.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.